Contemporary Oncology (Jan 2021)
Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study
Abstract
No abstracts available.Keywords